Clinical trials: Gastrointestinal Peptides and Hormones
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS